Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 11,667 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak Azamian sold 11,667 shares of the company’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total value of $801,639.57. Following the sale, the chief executive officer directly owned 45,385 shares in the company, valued at $3,118,403.35. This represents a 20.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS traded down $1.49 during midday trading on Thursday, reaching $66.75. The company had a trading volume of 461,600 shares, compared to its average volume of 672,393. Tarsus Pharmaceuticals, Inc. has a 12-month low of $38.51 and a 12-month high of $85.25. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21. The stock’s fifty day simple moving average is $69.59 and its 200-day simple moving average is $70.20.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. As a group, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on TARS shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Mizuho initiated coverage on shares of Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price objective on the stock. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $91.83.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Comerica Bank boosted its holdings in shares of Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after acquiring an additional 705 shares in the last quarter. Truvestments Capital LLC lifted its position in Tarsus Pharmaceuticals by 106.1% in the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after purchasing an additional 468 shares during the period. Rockefeller Capital Management L.P. lifted its position in Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares during the period. Osaic Holdings Inc. boosted its holdings in Tarsus Pharmaceuticals by 779.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after purchasing an additional 2,462 shares in the last quarter. Finally, Leonteq Securities AG purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $164,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published a set of 2026 estimates that materially narrow expected losses (FY2026 now seen at -$1.01 vs. broader consensus -$3.17) and forecast a positive Q4‑2026 EPS of $0.09 — a clear bullish catalyst that can support upside expectations. Lifesci upgrade report
• Positive Sentiment: Large institutional investors have been increasing stakes (RTW, Deep Track, Jennison, Vanguard, Morgan Stanley among others), keeping roughly 90% institutional ownership — steady buying from big funds tends to support share-price stability and upside over time. MarketBeat TARS coverage
• Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable: the average recommendation is “Moderate Buy” and some firms (Guggenheim, Oppenheimer) have raised targets while others are more cautious — this keeps the outlook constructive but not unanimous. Analyst consensus article
• Neutral Sentiment: Recent quarterly results: revenue beat estimates ($151.7M vs. $144.6M) but EPS slightly missed ($0.20 loss vs. $0.19 expected). Revenue strength is supportive; continued negative margins and guidance keep risk elevated until pipeline milestones materialize. Earnings summary
• Negative Sentiment: Insider selling: Director William J. Link sold 12,500 shares at an average $68.79 on March 16 (disclosed via SEC filing), reducing his stake by ~9.7%. Insider sales can create short‑term downward pressure or be interpreted by some investors as profit‑taking. InsiderTrades report (SEC Form 4)

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.